Cell Reports (Aug 2023)

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

  • Estefania Cuesta-Borràs,
  • Cándida Salvans,
  • Oriol Arqués,
  • Irene Chicote,
  • Lorena Ramírez,
  • Laia Cabellos,
  • Jordi Martínez-Quintanilla,
  • Alex Mur-Espinosa,
  • Alejandro García-Álvarez,
  • Jorge Hernando,
  • Juan Ramón Tejedor,
  • Oriol Mirallas,
  • Elena Élez,
  • Mario F. Fraga,
  • Josep Tabernero,
  • Paolo Nuciforo,
  • Jaume Capdevila,
  • Héctor G. Palmer,
  • Isabel Puig

Journal volume & issue
Vol. 42, no. 8
p. 112927

Abstract

Read online

Summary: Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through combining functional pulse-chase experiments in engineered cells and transcriptomic analyses, we identify DPPA3 as a master regulator of slow-cycling and chemoresistant phenotype in colorectal cancer (CRC). We find a vicious DPPA3-HIF1α feedback loop that downregulates FOXM1 expression via DNA methylation, thereby delaying cell-cycle progression. Moreover, downregulation of HIF1α partially restores a chemosensitive proliferative phenotype in DPPA3-overexpressing cancer cells. In cohorts of CRC patient samples, DPPA3 overexpression acts as a predictive biomarker of chemotherapeutic resistance that subsequently requires reduction in its expression to allow metastatic outgrowth. Our work demonstrates that slow-cycling cancer cells exploit a DPPA3/HIF1α axis to support tumor persistence under therapeutic stress and provides insights on the molecular regulation of disease progression.

Keywords